
John Garibotto joins Cellnovo’s Board
pharmafile | June 21, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Cellnovo, GaribottoÂ
UK-based medical device firm Cellnovo has appointed John Garibotto as a non-executive director.
Garibotto is a 20-year veteran of the medical device industry and has been instrumental in the development, formation, and financing of medical device companies such as the Insulet Corporation and TransVascular.
He is presently the founder and chief technology officer of Securus Medical Group.
“It is a real pleasure to welcome John as director,” said Eric Beard, Cellnovo’s executive chairman. “John has vast experience in complex medical device development. His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval.”
“I’m delighted to join the board of this outstanding company,” said Garibotto. “Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes. I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams.”
Related Content
Cellnovo, Roche sign deal to integrate diabetes platforms
Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug …






